Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 28

Sort by

Sort Order Select

Journal Articles

The Expression of BTG1 in De Novo AML Patients Regulated By Demethylation of Decitabine and Its Evaluation in the Deep Remission of Patients

Shiyuan Zhang, Mengyuan Li, Xiaojian Zhu, Hao Zhou, Bin Xu, Xiwen Tong, Su Shuai, Yi Zhu, Yi Xiao, Liang Huang, Dengju Li, Wei Huang, Jia Wei, Mei Huang, Donghua Zhang

Blood (2024) 144 (Supplement 1): 1401.

https://doi.org/10.1182/blood-2024-205864

Published: 2024

Journal Articles

Efficacy of Decitabine in Combination with IA Versus IA in Patients with Newly Diagnosed AML, a Multicenter, Prospective, Randomized Controlled Trial

Xiwen Tong, Bin Xu, Shiyuan Zhang, Xiaojian Zhu, Mengyuan Li, Su Shuai, Yi Zhu, Zhenqian Huang, Yaya Wang, Yi Xiao, Liang Huang, Dengju Li, Wei Huang, Jia Wei, Mei Huang, Zhiping Huang, Yuanyan Tang, Hongbo Ren, Donghua Zhang

Blood (2024) 144 (Supplement 1): 4276.

https://doi.org/10.1182/blood-2024-205769

Published: 2024

Journal Articles

Single Cell Multi-Omic Analysis of Tumor Microenvironment Evolution across the Disease Spectrum of Multiple Myeloma Identifies Differential Mechanisms of Immune Suppression

Minghao Dang, Hima Bansal, Maria Jose Acevedo-Calado, Li Qin, Wei Tan, Luz Yurany Moreno Moreno Rueda, Mei Huang, David Berrios Nolasco, Hans C. Lee, Krina K. Patel, Pei Lin, Sheeba K. Thomas, Donna M. Weber, Linghua Wang, Elisabet E. Manasanch, Robert Z. Orlowski

Blood (2023) 142 (Supplement 1): 89.

https://doi.org/10.1182/blood-2023-182902

Published: 2023

Journal Articles

Bone Marrow Fibrosis Changes Do Not Correlate with Efficacy Outcomes in Myelofibrosis: Analysis of More Than 300 JAK Inhibitor-Naïve Patients Treated with Momelotinib or Ruxolitinib

Blood (2022) 140 (Supplement 1): 821–823.

https://doi.org/10.1182/blood-2022-160409

Published: 2022

Journal Articles

Regulated Expression of GATA1 As a Gene Therapy Cure for Diamond-Blackfan Anemia

Richard A Voit, Xiaotian Liao, Blake Cohen, Myriam Armant, Elena Kamal, Mei-Mei Huang, William Clarke, David A. Williams, Akiko Shimamura, Vijay G. Sankaran

Blood (2022) 140 (Supplement 1): 986–987.

https://doi.org/10.1182/blood-2022-165848

Published: 2022

Journal Articles

Clinical Outcomes of Myelofibrosis Patients Following Immediate Transition to Momelotinib from Ruxolitinib

Ruben Mesa, Srdan Verstovsek, Uwe Platzbecker, Vikas Gupta, David Lavie, Pilar Giraldo, Jean-Jacques Kiladjian, Stephen T Oh, Timothy Devos, Francesco Passamonti, Miklos Egyed, Alessandro Vannucchi, Andrzej Pluta, Donal P McLornan, Jun Kawashima, Mei Huang, Bryan Strouse, Claire Harrison

Blood (2022) 140 (Supplement 1): 3983–3985.

https://doi.org/10.1182/blood-2022-159636

Published: 2022

Journal Articles

Momelotinib (MMB) Long-Term Safety: Pooled Data from Three Phase 3 Randomized-Controlled Trials (RCTs)

Blood (2022) 140 (Supplement 1): 9670–9672.

https://doi.org/10.1182/blood-2022-162543

Published: 2022

Journal Articles

Baseline Serum Ferritin Differentially Predicts W24 Transfusion Independence Response for Momelotinib and Ruxolitinib in Patients with Myelofibrosis

Stephen T. Oh, Aaron T. Gerds, Ruben A. Mesa, Vikas Gupta, Mei Huang, Sunhee Ro, Bryan Strouse, Barbara Jane Klencke, Srdan Verstovsek

Blood (2021) 138 (Supplement 1): 3638.

https://doi.org/10.1182/blood-2021-146623

Published: 2021

Journal Articles

Activity of transgene-produced B-domain–deleted factor VIII in human plasma following AAV5 gene therapy

Steffen Rosen, Stefan Tiefenbacher, Mary Robinson, Mei Huang, Jaydeep Srimani, Donnie Mackenzie, Terri Christianson, K. John Pasi, Savita Rangarajan, Emily Symington, Adam Giermasz, Glenn F. Pierce, Benjamin Kim, Stephen J. Zoog, Christian Vettermann

Blood (2020) 136 (22): 2524–2534.

https://doi.org/10.1182/blood.2020005683

Published: 2020

Includes: Supplemental data

Journal Articles

Once Weekly Versus Twice Weekly Carfilzomib Dosing in Patients with Relapsed and Refractory Multiple Myeloma (A.R.R.O.W.): Efficacy and Safety Analyzed By Age Group

Meletios A Dimopoulos, MD, Ruben Niesvizky, MD, Philippe Moreau, David S Siegel, MD PhD, Roman Hajek, MD PhD, Maria-Victoria Mateos, MD PhD, Michele Cavo, MD, Mei Huang, Anita Zahlten-Kumeli, Katja Weisel, MD

Blood (2018) 132 (Supplement 1): 3277.

https://doi.org/10.1182/blood-2018-99-118448

Published: 2018

Journal Articles

Efficacy and Safety of Once-Weekly vs Twice-Weekly Carfilzomib Plus Dexamethasone: Subgroup Analysis of the Phase 3 A.R.R.O.W. Study (NCT02412878) By Prior Lines

Philippe Moreau, A Keith Stewart, MB, ChB, Antonio Lazzaro, Meletios A Dimopoulos, MD, Michele Cavo, MD, Sikander Ailawadhi, Karim Iskander, Mei Huang, Anita Zahlten-Kumeli, Maria-Victoria Mateos, MD PhD

Blood (2018) 132 (Supplement 1): 3244.

https://doi.org/10.1182/blood-2018-99-114863

Published: 2018

Journal Articles

Efficacy and Safety of Carfilzomib and Dexamethasone in Lenalidomide Exposed and Refractory Multiple Myeloma Patients: Combined Analysis of Carfilzomib Trials

Maria-Victoria Mateos, MD PhD, Jesus G. Berdeja, MD, Meletios A Dimopoulos, MD, David S Siegel, MD PhD, P Joy Ho, MBBS(Syd) DPhil(Oxon) FRACP FRCPA FFSc(RCPA), Mei Huang, Martina Sersch, Anita Zahlten-Kumeli, Amy S Kimball, Katja Weisel, MD

Blood (2018) 132 (Supplement 1): 1963.

https://doi.org/10.1182/blood-2018-99-112600

Published: 2018

Journal Articles

Iron Overload Status in Patients with Non-Transfusion-Dependent Thalassemia in China

Rong rong Liu, MD, Yu mei Huang, Peng Peng, MD, Xiao yun Wei, Yu Lei, Jiao di Liu, Gao hui Yang, Yong rong Lai, MD

Blood (2016) 128 (22): 1287.

https://doi.org/10.1182/blood.V128.22.1287.1287

Published: 2016

Journal Articles

Updated Results from a Phase 2 Extension Study of Patients with Multiple Myeloma or Solid Tumors Previously Enrolled in Carfilzomib Company-Sponsored Phase 1 and 2 Clinical Trials (PX-171-010)

David S. Siegel, MD PhD, Jesus G. Berdeja, MD, Jeffrey R. Infante, MD, Jonathan L. Kaufman, MD, Michael (Luhua) Wang, MD, Thomas G. Martin, MD, Ruben Niesvizky, MD, Frederic J. Reu, MD, Sundar Jagannath, MD, Kanya Rajangam, MDPhD, Mei Huang, MS, Ravi Vij, MD

Blood (2014) 124 (21): 2134.

https://doi.org/10.1182/blood.V124.21.2134.2134

Published: 2014

Journal Articles

Relationship Of Serum Free Light Chain Reduction To Best Overall Response In Phase 2 Single-Agent and Combination Studies Of Carfilzomib In Patients With Relapsed Or Relapsed and/Or Refractory Multiple Myeloma

Ravi Vij, MD, Michael Wang, MD, Sundar Jagannath, MD, Ruben Niesvizky, MD, Andrzej J. Jakubowiak, MD, PhD, Edward Kavalerchik, MD, Mei Huang, MS, David S. Siegel, MD, PhD

Blood (2013) 122 (21): 1965.

https://doi.org/10.1182/blood.V122.21.1965.1965

Published: 2013

Journal Articles

Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma

Michael Wang, Tom Martin, William Bensinger, Melissa Alsina, David S. Siegel, Edward Kavalerchik, Mei Huang, Robert Z. Orlowski, Ruben Niesvizky

Blood (2013) 122 (18): 3122–3128.

https://doi.org/10.1182/blood-2013-07-511170

Published: 2013

Includes: Supplemental data

Journal Articles

Egress of CD19 + CD5 + cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients

Betty Y. Chang, Michelle Francesco, Martin F. M. De Rooij, Padmaja Magadala, Susanne M. Steggerda, Min Mei Huang, Annemieke Kuil, Sarah E. M. Herman, Stella Chang, Steven T. Pals, Wyndham Wilson, Adrian Wiestner, Marcel Spaargaren, Joseph J. Buggy, Laurence Elias

Blood (2013) 122 (14): 2412–2424.

https://doi.org/10.1182/blood-2013-02-482125

Published: 2013

Includes: Supplemental data

Journal Articles

A Phase 2 Study of Prolonged Carfilzomib Therapy in Patients with Multiple Myeloma Previously Enrolled in Carfilzomib Clinical Trials.

David S. Siegel, MD, PhD, Michael Wang, M.D., Thomas G Martin, III, MD, Jeffrey R. Infante, MD, Jonathan L. Kaufman, MD, Kanya Ranjangam, MD, PhD, Mei Huang, MS, Elizabeth Bilotti, MSN, RN, Ravi Vij, MD

Blood (2012) 120 (21): 2962.

https://doi.org/10.1182/blood.V120.21.2962.2962

Published: 2012

Journal Articles

Egress of CD19 + CD5 + Cells Into Peripheral Blood Following Treatment with the Bruton Tyrosine Kinase Inhibitor, PCI-32765, in Mantle Cell Lymphoma Patients

Betty Y Chang, PhD, Michelle Francesco, Padmaja Magadala, Min Mei Huang, PhD, Marcel Spaargaren, PhD, Joseph J. Buggy, PhD, Laurence Elias, MD

Blood (2011) 118 (21): 954.

https://doi.org/10.1182/blood.V118.21.954.954

Published: 2011

Journal Articles

Triptolide Induces Apoptosis In Acute Lymphoblastic Leukemia Cells by Inhibition of the Oncoprotein MDM2

Mei Huang, Lubing Gu, MD, Muxiang Zhou, MD

Blood (2010) 116 (21): 4934.

https://doi.org/10.1182/blood.V116.21.4934.4934

Published: 2010

NARROW

The Expression of BTG1 in De Novo AML Patients Regulated By Demethylation of Decitabine and Its Evaluation in the Deep Remission of Patients

Efficacy of Decitabine in Combination with IA Versus IA in Patients with Newly Diagnosed AML, a Multicenter, Prospective, Randomized Controlled Trial

Single Cell Multi-Omic Analysis of Tumor Microenvironment Evolution across the Disease Spectrum of Multiple Myeloma Identifies Differential Mechanisms of Immune Suppression

Bone Marrow Fibrosis Changes Do Not Correlate with Efficacy Outcomes in Myelofibrosis: Analysis of More Than 300 JAK Inhibitor-Naïve Patients Treated with Momelotinib or Ruxolitinib

Regulated Expression of GATA1 As a Gene Therapy Cure for Diamond-Blackfan Anemia

Clinical Outcomes of Myelofibrosis Patients Following Immediate Transition to Momelotinib from Ruxolitinib

Momelotinib (MMB) Long-Term Safety: Pooled Data from Three Phase 3 Randomized-Controlled Trials (RCTs)

Baseline Serum Ferritin Differentially Predicts W24 Transfusion Independence Response for Momelotinib and Ruxolitinib in Patients with Myelofibrosis

Activity of transgene-produced B-domain–deleted factor VIII in human plasma following AAV5 gene therapy

Once Weekly Versus Twice Weekly Carfilzomib Dosing in Patients with Relapsed and Refractory Multiple Myeloma (A.R.R.O.W.): Efficacy and Safety Analyzed By Age Group

Efficacy and Safety of Once-Weekly vs Twice-Weekly Carfilzomib Plus Dexamethasone: Subgroup Analysis of the Phase 3 A.R.R.O.W. Study (NCT02412878) By Prior Lines

Efficacy and Safety of Carfilzomib and Dexamethasone in Lenalidomide Exposed and Refractory Multiple Myeloma Patients: Combined Analysis of Carfilzomib Trials

Iron Overload Status in Patients with Non-Transfusion-Dependent Thalassemia in China

Updated Results from a Phase 2 Extension Study of Patients with Multiple Myeloma or Solid Tumors Previously Enrolled in Carfilzomib Company-Sponsored Phase 1 and 2 Clinical Trials (PX-171-010)

Relationship Of Serum Free Light Chain Reduction To Best Overall Response In Phase 2 Single-Agent and Combination Studies Of Carfilzomib In Patients With Relapsed Or Relapsed and/Or Refractory Multiple Myeloma

Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma

Egress of CD19 + CD5 + cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients

A Phase 2 Study of Prolonged Carfilzomib Therapy in Patients with Multiple Myeloma Previously Enrolled in Carfilzomib Clinical Trials.

Egress of CD19 + CD5 + Cells Into Peripheral Blood Following Treatment with the Bruton Tyrosine Kinase Inhibitor, PCI-32765, in Mantle Cell Lymphoma Patients

Triptolide Induces Apoptosis In Acute Lymphoblastic Leukemia Cells by Inhibition of the Oncoprotein MDM2

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only